Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma to announce first quarter results on August 12, 2014

July 30, 2014, Mumbai: On August 12, 2014, Sun Pharma will announce results for the first quarter ending June 30, 2014. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (10.00 am IST, August 13, 2014)

The Company will conduct an hour long call at 10.00 am IST on August 13, 2014 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Earnings release	August 12, 2014	www.sunpharma.com
Earnings conference call	10.00 am IST, August 13, 2014	Primary Number : +91 22 3960 0899 Secondary Number : +91 22 6746 8324 Via audio webcast, details of which will be made available on www.sunpharma.com
Replay of conference call	August 13, 2014 to August 19 2014	India: +91 22 3065 2322 ID: 786742 Via audio webcast playback, details of which will be made available on www.sunpharma.com

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 75% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2014, overall revenues were at US$2.7 billion, of which US contributed US$1.6 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, and ophthalmology. The company has strong skills in product development, process

Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685
CIN: L24230GJ1993PLC019050
www.sunpharma.com

chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Nimish Desai
Tel +91 22 6645 5645, Xtn 5717
Tel Direct +91 22 66455717
Mobile +91 98203 30182
E mail nimish.desai@sunpharma.com

Frederick Castro
Tel +91 22 6645 5645, Xtn 5964
Tel Direct +91 22 66455964
Mobile +91 99206 665176
E mail frederick.castro@sunpharma.com